Press Releases

Jun 21, 2021
Veteran pharmaceutical executive with proven cell and gene therapy development experience in Asia , formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI --(BUSINESS WIRE)--Jun. 21, 2021-- Allogene Overland Biopharm (Allogene
Jun 04, 2021
ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete
May 19, 2021
ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL) Overall Response Rate (ORR) of 75% and CR Rate of 50% Across Histologies in CAR T Naïve Patients, on Par with Data from Pivotal Trials
May 12, 2021
Webinar Scheduled for 2:30 PM PT / 5:30 PM ET SOUTH SAN FRANCISCO, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on
May 05, 2021
CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included Allogene to Host
Displaying 1 - 10 of 20
Print Page
Email Alerts
RSS Feeds
Investor Contacts